Compare · AMGN vs TVGN
AMGN vs TVGN
Side-by-side comparison of Amgen Inc. (AMGN) and Tevogen Bio Holdings Inc. (TVGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and TVGN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $197.69B, about 11129.0x TVGN ($17.8M).
- Over the past year, AMGN is up 24.2% and TVGN is down 93.1% - AMGN leads by 117.4 points.
- TVGN has been more active in the news (11 items in the past 4 weeks vs 1 for AMGN).
- AMGN has more recent analyst coverage (25 ratings vs 2 for TVGN).
- Company
- Amgen Inc.
- Tevogen Bio Holdings Inc.
- Price
- $366.18-1.45%
- $4.25-13.00%
- Market cap
- $197.69B
- $17.8M
- 1M return
- +5.29%
- -61.64%
- 1Y return
- +24.25%
- -93.12%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2022
- News (4w)
- 1
- 11
- Recent ratings
- 25
- 2
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest AMGN
- FDA Approval for REPATHA issued to AMGEN INC
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
- AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- Ember LifeSciences announces new strategic investments boosting Series A to $27M
- Director Miles Amy E was granted 665 shares, increasing direct ownership by 13% to 5,640 units (SEC Form 4)
- Director Kullman Ellen Jamison was granted 665 shares, increasing direct ownership by 5% to 14,536 units (SEC Form 4)
- Director Klotman Mary E. was granted 665 shares, increasing direct ownership by 43% to 2,211 units (SEC Form 4)
- Director Jacks Tyler was granted 665 shares, increasing direct ownership by 4% to 18,284 units (SEC Form 4)
Latest TVGN
- Tevogen Bio Announces 2026 Annual Meeting of Stockholders
- Director Sordillo Victor J. was granted 40,000 shares, increasing direct ownership by 347% to 51,539 units (SEC Form 4)
- Chief Executive Officer Saadi Ryan H. was granted 1,220,000 shares, increasing direct ownership by 49% to 3,705,689 units (SEC Form 4)
- Director Podlogar Susan M was granted 40,000 shares, increasing direct ownership by 461% to 48,678 units (SEC Form 4)
- Director Patton Curtis L. was granted 40,000 shares, increasing direct ownership by 165% to 64,192 units (SEC Form 4)
- Director Goh Keow Lin was granted 40,000 shares, increasing direct ownership by 461% to 48,678 units (SEC Form 4)
- Director Feike Jeffrey L. was granted 40,000 shares, increasing direct ownership by 243% to 56,435 units (SEC Form 4)
- Chief Financial Officer Desai Kirti was granted 40,000 shares, increasing direct ownership by 20% to 242,983 units (SEC Form 4)
- SEC Form S-8 filed by Tevogen Bio Holdings Inc.
- SEC Form 424B3 filed by Tevogen Bio Holdings Inc.